Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y. Nabet, David S. Shames, Matthew Fernandez et al.|Cancer Cell|2024Cited by 154
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Huafei Li et al.|Lung Cancer|2024Cited by 66